Professional Documents
Culture Documents
Review
Abstract
The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphos-
phonates (alendronate, risedronate and ibandronate), mainly used for the treatment of os-
teoporosis, have been associated with adverse events from the upper gastrointestinal tract,
acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal
pain, osteonecrosis of the jaw and ocular events. Intravenous bisphosphonates (pamidronate,
ibandronate and zoledronic acid), used in oncology and for the treatment of osteoporosis, have
been associated with all the above adverse events, except those from the upper gastrointestinal
tract. Moreover, pamidronate and zoledronic acid have been associated with renal toxicity.
Association of bisphosphonates with atrial fibrillation and atypical fractures of the femoral
diaphysis remains uncertain. There are a few case reports relating bisphosphonates to cutane-
ous reactions, oral ulcerations, hepatitis and esophageal cancer. Generally, intravenous are
more potent than oral bisphosphonates and the frequency and severity of some of the bisphos-
phonate-associated adverse events are dose and potency dependent.
Key words: Adverse events, Bisphosphonates intravenous, Bisphosphonates oral, Osteoporosis
>75 years, with previous upper GI tract disease or were excluded from participating in the FIT study5 if
using non-steroidal anti-inflammatory drugs).5 Cryer they had had upper GI tract bleeding within the past
et al6 also found that alendronate 70 mg once-weekly, five years requiring hospitalization or transfusion;
used concomitantly with non-steroidal anti-inflam- documented recurrent or recent ulcer disease (two
matory drugs, did not increase upper GI adverse episodes in the preceding five years or one episode in
events relative to placebo over three months. In a the preceding 12 months); experienced esophageal or
multi-center, 3-month, randomized, double-blind, gastric varices; or used medication daily for dyspepsia.5
placebo-controlled study by Greenspan et al,7 the Patients with disorders of esophageal motility, such
tolerability of once-weekly alendromate was evalu- as stricture or achalasia, were also excluded from
ated in American patients with osteoporosis. A total another study.7 Therefore, these exclusion criteria
of 11% of the alendronate patients and 13% of the may be considered as contraindications for the oral
placebo patients reported upper GI tract adverse bisphosphonates. In these trials, 5,7 women with past
events. Discontinuations due to drug-related upper or current evidence of other upper GI tract diseases
GI tract events occurred in 3% of alendronate patients (hiatal hernia, esophageal reflux, esophagitis and
and 1% of placebo patients. The differences between heartburn) were eligible for participation in the trial.
the treatment groups for both these end points of the Active reflux or non-reflux esophagitis are not cur-
study were not significant.7 The multi-center study rently considered a contraindication for oral bisphos-
by Eisman et al8 included patients from Europe, the phonates, although this condition may sometimes be a
Americas, Africa and Asia-Pacific and was similar in complicated problem. Esophageal reflux is a common
design to the study of Greenspan et al.7 The authors disturbance affecting about 20% of the general popu-
of these studies7,8 concluded that alendronate 70 mg lation11and can result in Barrett’s esophagus, which
administered once-weekly to women and men with predisposes to the development of adenocarcinoma
osteoporosis has an upper GI and overall tolerability of the esophagus. Barrett’s esophagus should be a
profile similar to that of placebo. contraindication for bisphosphonates.
Regarding the association of bisphosphonate
2. Renal toxicity
use with upper GI tract adverse events, Cryer and
Bauer9 reviewed the evidence originating from ani- The earliest clinical use of a bisphosphonate (eti-
mal and laboratory studies, epidemiological studies, dronate) was for the treatment of Paget’s disease and
endoscopy trials and randomized controlled trials. dates back to 1971.12 Subsequently, with the use of
They concluded that the evidence from randomized intravenous bisphosphonates (etidronate, clodronate)
controlled trials suggests little or no increase in the for the treatment of malignant hypercalcaemia due to
risk of upper GI tract problems if bisphosphonates osteolytic tumor-induced bone disease,12 several cases
are administered properly. The evidence suggests that of renal failure were reported.13 A possible mecha-
many upper GI tract adverse events reported during nism of the renal toxicity was considered at that time
therapy with bisphosphonates may reflect a high to be the strong affinity of the bisphosphonates for
background incidence of upper GI tract complaints metal ions (calcium included) and their tendency to
and an increased sensitivity to detection rather than form soluble or insoluble complexes and aggregates
a causal relationship to therapy.9 Risedronate and with metal ions, notably when large amounts of the
ibandronate seem to have a GI tolerability similar drugs were infused rapidly.12 These aggregates could
to that of alendronate.9,10 be held back in the kidney and cause renal injury.12
This theory, however, is not supported in the recent
Current evidence, as presented above, should be
literature and the mechanism of the renal toxicity of
reassuring to practitioners and patients in that the use
bisphosphonates remains largely unknown.
of oral bisphosphonates for treatment of osteoporosis
does not increase the likelihood of upper GI adverse Many cases of renal toxicity were reported with
events on condition that the patients adhere to the the newer intravenous bisphosphonates, pamidronate
rules of correct dosing and mode of intake of these and zoledronic acid,14,15 but not with ibandronate,16
drugs. With regard to upper GI tract safety, women used in patients with malignant disease. Patterns of
Bisphosphonate-associated adverse events 99
nephrotoxicity with these drugs include toxic acute and hip BMD. Klawansky et al21 found that 24% of
tubular necrosis and collapsing focal segmental glo- women with osteoporosis (ages 20-80+) had severe
merulosclerosis.17 The renal toxicity of the intravenous renal compromise (creatinine clearance by the C-G
bisphosphonates used in patients with malignant formula <35 ml/min). For ages 80+ the proportion
diseases involving bone is probably enhanced by risk rises to 54%. In women with osteopenia (ages 80+)
factors for kidney function which may be present in the prevalence of severe renal compromise was 37%.
these patients: pre-existing Chronic Kidney Disease Thus, a substantial proportion of candidates for treat-
(CKD), multiple myeloma, hypercalcaemia, hyperten- ment of osteoporosis or osteopenia have significant
sion, diabetes mellitus, advanced age, chemotherapy renal function compromise.21
or previous treatment with a bisphosphonate.16,18
Renal failure has been reported after the use of
Important factors which may increase renal toxicity
intravenous bisphosphonates15 and therefore intra-
of the intravenous bisphosphonates are higher dose,
venous bisphosphonates should be used with caution
shorter infusion times or dose interval lower than
for the treatment of patients with osteoporosis, who
recommended.16,19 The total dose of the drug which
have compromised renal function.21 Oral risedronate
has been administered during a long-term treatment
proved to be safe for the treatment of osteoporosis
may also play a role because of its probable cumula-
in patients with compromised renal function in one
tive effect.20
study.23 Oral bisphosphonates are not associated with
There is no evidence till now that oral bisphospho- significant nephrotoxicity,17 although there have been
nates, as they are used for treatment of osteoporosis, exceptions to this rule.24
have been associated with significant renal toxicity.
Calculated creatinine clearance is essential for
However, this may be an underestimation because
the assessment of renal function in older persons
many of the trials on the efficacy and safety of the
with osteoporosis not only at baseline but also during
bisphosphonates for the treatment of osteoporosis
treatment with bisphosphonates.
excluded patients with severe CKD. Thus, based
on the FDA-approved labeling, which recommends 3. Ocular adverse events
that bisphosphonates should be used with caution The most common ocular side effect of bisphos-
in patients with creatinine clearance less than 30 phonates is nonspecific conjunctivitis,25 which usu-
ml/min, clinicians probably were not treating with ally improves without specific therapy and despite
bisphosphonates patients with pre-existing CKD who continuing treatment with a bisphosphonate. Rarely,
may be more susceptible to renal injury by these drugs. treatment with a non-steroidal anti-inflammatory eye
Therefore, there is uncertainty as to how the clini- drop is required.25 A few cases of other ocular side
cian should evaluate the renal function of a patient effects such as eyelid edema, optic or retrobulbar
candidate for treatment with a bisphosphonate and neuritis, periorbital edema, cranial nerve palsy and
about the management of the patient with CKD. ptosis have been reported.25 Uveitis and scleritis
Renal function declines with advancing age.21,22 are the most serious ocular side effects of bisphos-
Renal function is not accurately assessed by serum phonate therapy and require the discontinuation of
creatinine measurements in older adults and measure- bisphosphonate treatment.25,26 Several reported cases
ment of the creatinine clearance is recommended for of uveitis and scleritis which occurred during therapy
this purpose using either the Cockcoft-Gault (C-G) with bisphosphonates may be classified as “certain”
formula or the Modification of Diet in Renal Disease side effects of the bisphosphonates because they
(MDRD) equation.20,21 Jassal et al22 reported that fulfilled the criteria of the WHO Causality Guide of
48.8% of healthy seniors had 30-59 ml/min/1.73m2 Suspected Adverse Reactions:25 temporal relationship
creatinine clearance calculated by the C-G formu- to bisphosphonate therapy, absence of concurrent dis-
la, 2.7% had <30 ml/min/1.73m2 and only 5.5% of ease predisposing to these adverse events and positive
these older community-dwelling persons had values tests at dechallenge and rechallenge.25 Fraunfelder
>90 ml/min/1.73m2. There was a significant linear et al,25 after reviewing the inflammatory ocular side
correlation between creatinine clearance by C-G effects (scleritis and uveitis) caused by intravenous
100 P.D. Papapetrou
occurs mainly after the first infusion of a nitrogen- conditions, bisphosphonate-induced hypocalcaemia
containing bisphosphonate in bisphosphonate naive often subsides despite continued bisphosphonate
patients and is rare in subsequent infusions of the therapy; symptomatic hypocalcaemia seems to be
drug. 36,37 The AFR is maximally expressed 28-36 uncommon after oral bisphosphonate treatment and
hours of IV administration of nitrogen-containing usually occurs weeks after the start of treatment. The
bisphosphonates and subsides 2-3 days later despite more potent intravenous bisphosphonates may cause
continuous treatment.36 Fever, malaise and myalgia symptomatic hypocalcaemia more often than oral
have been reported in 30-35% of patients receiving bisphosphonates, usually within days after the bisphos-
an initial dose of an intravenous nitrogen-containing phonate infusion. Thus, symptomatic hypocalcaemia
bisphosphonate.37 However, in a group of women with and hypomagnesemia occurred in 8% of patients
a history of breast cancer, who were treated with zole- with various malignancies treated with zoledronic
dronic acid for osteoporosis secondary to aromatase acid despite prophylactic administration of vitamin
inhibitor treatment, the incidence of these complaints D and calcium supplements.44 Risk factors for severe
was much higher, i.e. about 70%. 38 Intravenously bisphosphonate-induced hypocalcaemia are pre-exist-
administered nitrogen-containing bisphosphonstes ing hypoparathyroidism,45,46 parathyroid dysfunction
(pamidronate, zoledronic acid and ibandronate) during thyroidectomy in a patient receiving chronic
are known to cause a typical systemic AFR. Mild bisphosphonate therapy,47 vitamin D deficiency46,48
to moderate AFR may also occur with the initial and renal failure.44,49 The bisphosphonate-induced
exposure to once-weekly or once-monthly doses of hypocalcaemia and secondary hyperparathyroidism
oral bisphosphonates, that is, more often than with can be avoided or attenuated by the administration of
the daily formulations of the drugs.39 This type of adequate vitamin D and calcium supplements, start-
reaction has not been observed with non nitrogen- ing about two weeks before the administration of the
containing bisphosphonates (etidronate, clordronate bisphosphonate. Berruti et al50 emphasized the need
and tiludronate).37 to treat effectively the secondary hyperparathyroid-
ism in cancer patients because of the ability of high
The bisphosphonate-induced AFR is mediated PTH to promote tumor growth.
by interleukin 6,40 tumor necrosis factor α and other
proinflammatory cytokines released by receptor-ac- 6. Musculoskeletal pain
tivated γδT cells and macrophages.37,41 The activation An alert by the Food and Drug Administration
of γδT cells can be inhibited by statins in vitro,41 (FDA) on Jan. 7, 2008, stated the following: “There
although atorvastatin was ineffective on AFR fol- is a possibility of severe and sometimes incapacitating
lowing bisphosphonate infusion in children.42 The bone, joint, and/or muscle (musculoskeletal) pain in
bisphosphonate-induced AFR is usually benign and patients taking bisphosphonates. The severe mus-
self-limited and can be treated with antipyretics. culoskeletal pain may occur within days, months or
years after starting a bisphosphonate. Some patients
5. Hypocalcaemia and secondary have reported complete relief of symptoms after dis-
hyperparathyroidism continuing the bisphosphonate, whereas others have
Nitrogen-containing bisphosphonates are potent reported slow or incomplete resolution. This severe
inhibitors of osteoclastic bone resorption. As a result of musculoskeletal pain is in contrast to the acute phase
this effect, six weeks after starting alendronate therapy, response characterized by fever, chills, bone pain,
serum calcium and phosphorus decrease and intact myalgias and arthralgias that sometimes accompany
Parathyroid Hormone (PTH) significantly increase in initial administration of intravenous bisphosphonates
a dose-dependant fashion. Calciuria and phosphatu- and may occur with initial exposure to once-weekly
ria also decrease.43 The increased PTH antagonizes or once-monthly doses of oral bisphosphonates. The
the effect of bisphosphonates in bone and conserves symptoms related to the acute phase response tend
calcium by increasing tubular reabsorption of calcium to resolve within several days with continuing drug
in the kidneys and by stimulating the kidneys to pro- use”.51 Between 1995 and 2002, the FDA received
duce 1,25-dihydroxyvitamin D. Thus, under normal reports of severe bone, joint and/or muscle pain that
102 P.D. Papapetrou
developed in 112 women and four men after start- with osteoporosis and can lead to clinical osteoma-
ing alendronate therapy. Pain affected bones, joints lacia with severe musculoskeletal pain involving the
and muscles all over the body and was sometimes lower back, pelvis, upper legs and ribs.57 Failure to
migratory. It was often described as “severe, extreme, prescribe adequate vitamin D and calcium supple-
disabling or incapacitating”. The doses of alendronate ments along with the bisphosphonate or the patient’s
were 5mg/d (4%), 10mg/d (74%), 20 to 35mg/d (4%) non-compliance with the supplements may cause
and 70mg/wk (18%). The onset of pain after start- clinical osteomalacia during bisphosphonate therapy
ing alendronate therapy ranged from same day to 52 for osteoporosis. A hypothetical mechanism of bone
months (mean=91 days, median=14 days). The FDA pain associated with bisphosphonate treatment may
received six reports of severe bone, joint or muscle be the following: in some cases of bisphosphonate-
pain for risedronate. 52 Bock et al53 studied the oc- induced secondary hyperparathyroidism43 there may
currence of musculoskeletal events in a large cohort be a relatively smaller reduction of bone turnover
of patients with osteoporosis who were treated with caused by the bisphosphonate because of the antago-
alendronate or risedronate daily or once-weekly. Only nistic effect of the high PTH. In such cases, bone
events starting within 48 hours after initiating bisphos- turnover higher than expected from treatment with a
phonate therapy and without any other evident cause bisphosphonate unopposed by a high PTH may lead
were evaluated. No patient treated with alendronate to relatively higher bone uptake of bisphosphonate
10mg/d or risedronate 5mg/d experienced significant and higher than average concentration of the drug
musculoskeletal events. In contrast, 20% of patients in the bone microenvironment. This in turn may
treated initially with alendronate 70mg/wk and 25% result in a localized, relatively increased bisphospho-
of patients treated initially with risedronate 35mg/wk nate-induced production of interleukin-6 and other
experienced events such as arthralgia (12.6%), back proinflammatory cytokines41 and an inflammatory
pain (9.1%), myalgia (4.2%), bone pain (4.2%), chest reaction confined to bones. On the other hand, the
pain (1.8%) and fever (1.2%). Remarkably, none of the high PTH in secondary hyperparathyroidism is known
patients who were initially treated with daily bisphos- to cause elevated interleukin-6 levels58 and thus higher
phonate reported any musculoskeletal event when bisphosponate concentration in bone, and high PTH
they were changed later to a once-weekly regimen. may have a synergistic effect in increased production
The authors suggested that pretreatment with a daily of interleukin-6.
dose of bisphosphosnate for about two weeks before 7. Osteonecrosis of the jaw
changing to the once-weekly regimen may desensitize
In 2002, the FDA received reports of several
the patients to musculoskeletal adverse events. 53 It is
patients with cancer, treated with the intravenous
very likely that the oral bisphosphonate-associated
bisphosphonate zoledronic acid, who developed os-
musculoskeletal adverse events reported by Bock et
teonecrosis of the jaw (ONJ).59 In the following year,
al53 occurred in the setting of an otherwise moderate
Marx60 reported on a series of 36 patients with ONJ
acute phase reaction, in contrast to the severe bone,
who were treated with pamidronate or zoledronic
joint and muscle pain reported by the FDA, potentially
acid. A second report in 2004 by Ruggiero et al61
unrelated to systemic acute phase reaction. 51,52
comprised 63 patients with ONJ, of whom 56 had
The pathological basis of the delayed painful received intravenous bisphosphonates for cancer,
bisphosphonate-associated adverse events remains and seven were treated with oral bisphosphonates for
undetermined in most cases. 51,52 Several cases of osteoporosis. In the report by Bamias et al,62 among
bisphosphonste-associated synovitis, confirmed by 252 patients with various malignancies treated with
positive rechallenge testing, were reported. 54,55 A bisphosphonates 17 (6.7%) developed ONJ. The inci-
case of acute polyarthritis and myalgia with positive dence of ONJ increased with time of exposure to the
rechallenge testing occurred 12 hours after the first drugs from 1.5% among patients treated for four to
ingestion of alendronate 70mg. 56 Severe vitamin 12 months, to 7.7% for treatment of 37 to 48 months.62
D deficiency, with 25-hydroxyvitamin D levels less The association of ONJ with bisphosphonate therapy
than 20 nmol/L, is not uncommon in elderly patients is discussed in a report of a task force of the American
Bisphosphonate-associated adverse events 103
Society for Bone and Mineral Research.63 The task Potential preventive measures for bisphosphonate-
force defined ONJ as the presence of exposed bone in related ONJ include: a) a routine clinical dental exami-
the maxillofacial region that did not heal within eight nation before initiating bisphosphonate therapy and,
weeks after identification by a health care provider. if possible, postponing the bisphosphonate therapy
The total number of reported cases of bisphospho- until the dental treatment has been carried out;65,66
nate-associated ONJ in patients with osteoporosis b) discontinuation of oral bisphosphonates in asymp-
or Paget’s disease was 64 (57 cases that occurred in tomatic patients, if systemic conditions permit, for a
association with treatment for osteoporosis and seven period of three months prior to and three months
cases that occurred in association with treatment of following elective invasive dental surgery; c) specific
Paget’s disease). The risk of ONJ associated with oral treatments for patients with established diagnosis of
bisphosphonate therapy for osteoporosis or Paget’s ONJ.66,67
disease was estimated to range between 1/10,000 and
1/100,000 patient-treatment years, although the true The risk of developing ONJ associated with oral
incidence may be higher. The risk of ONJ in patients bisphosphonates, while exceedingly small, appears
with cancer treated with high doses of intravenous to increase when the duration of therapy exceeds
bisphosphonates is in the range of 1-10 per 100 patients three years. This time-frame may be shortened in
(depending on duration of therapy).63 The incidence the presence of certain comorbidities, such as chronic
of ONJ in the general population or in untreated corticosteroid use.66
patients with osteoporosis is not known. Among 368 Marx et al67 found that serum type 1 collagen
reported cases of bisphosphonate-associated ONJ, C-terminal telopeptide (CTX) was related to the
the disease affected the mandible in 65%, the maxilla risk for ONJ. Thus, patients with CTX values less
in 26% and both sites in 9% of the cases. One third than 100pg/ml had high risk for ONJ, patients with
of the cases were painless. Sixty percent of cases oc- values of CTX between 100pg/ml and 150pg/ml had
curred after tooth extraction or other oral surgery moderate risk and patients with CTX values above
and the remaining spontaneously.64 The risk factors 150pg/ml had minimal risk. Therefore, the authors
specific to ONJ include head and neck radiotherapy suggested discontinuing the bisphosphonate and al-
(resulting in so-called osteoradionecrosis), periodontal lowing the bone turnover to recover as indicated by
disease, dental procedures involving bone surgery, CTX level above 150pg/ml. This constitutes a useful
edentulous regions and trauma from poorly fitting guideline as to when oral surgical procedures can be
dentures. Additional risk factors in cancer patients accomplished with the least risk.
include the underlying malignancy, chemotherapy,
corticosteroids and systemic or regional infection. A considerable body of literature on ONJ associ-
Pancytopenia, secondary to cancer and/or cancer ated with bisphosphonate therapy has been accumu-
treatment is a risk for infection and osteomyelitis. lated consisting mainly of case reports or case reports
Vascular insufficiency due to thrombosis caused series and reviews. Despite the extensive publicity,
by coagulopathies has been associated with ONJ.65 there is still controversy about bisphosphonates as
Drug-related risk factors include the potency of the causative factors for ONJ. In cancer patients treated
particular bisphosphonate-the intravenous bisphos- with intravenous bisphosphonates, the cause of ONJ
phonates zoledronic acid and pamidronate being is uncertain because of the coexistence of several
more potent than the oral bisphosphonates-and the confounding risk factors for ONJ. In patients with
longer duration of therapy. Patients with a history of osteoporosis treated with oral bisphosphonates, ONJ
inflammatory dental disease, e.g. periodontal and is rare and skepticism about the potential association
dental abscesses, have a seven-fold increased risk between oral bisphosphonate use and ONJ has been
for developing ONJ. Diabetes, smoking, alcohol use expressed.68,69 Historical evidence that bisphospho-
and poor oral hygiene are thought to be risk factors nates can be a cause of ONJ was provided recently
for ONJ.66 The diagnosis of ONJ is made by visual by Marx.70 Between 1858 and 1906, there was an
inspection.65 Early identification of ONJ may be epidemic of ONJ named “phossy jaw” among work-
achieved by bone imaging techniques.63 ers in match-making factories who inhaled fumes
104 P.D. Papapetrou
of “yellow phosphorus”. Marx points out that yel- to show any difference in the frequency of severe
low phosphorus can react in the human body with or all cases of atrial fibrillation between zoledronic
H2O, CO2 and amino acids such as lysine; as a result, acid and placebo treated patients.77 Furthermore,
bisphosphonates, almost identical to alendronate and analysis of the data from the risedronate RCT did
pamidronate, are formed.70 The mechanism by which not show any difference in atrial fibrillation frequency
bisphosphonates may cause ONJ remains unclear. between active drug and placebo treated patients.78
Ardine et al71 reported that patients with bisphos- Two recent case-control studies investigated whether
phonate-associated ONJ had persistently higher patients who presented with atrial fibrillation were
PTH levels compared to controls without ONJ and treated more often with bisphosphonates at any time79
they suggested that high PTH may be involved in the or currently80 compared to control patients without
pathogenesis of ONJ. Evidence against this theory is atrial fibrillation. In an American study,79 a group of
that in patients with primary hyperparathyroidism 719 women with atrial fibrillation was compared to a
and elevated PTH, lesions in the oral cavity include group of 966 without atrial fibrillation. In the atrial
reduced radicular lamina dura, reduced interdental fibrillation group 6.5% of the women were treated
alveolar bone density and reduced cortical bone at with alendromate at any time, compared to 4.1% of
the gonial index,72 whereas the bisphosphonate-as- the women without atrial fibrillation (p=0.03). Thus,
sociated ONJ is characterized by osteopetrosis-like the risk of atrial fibrillation was greater among the
osseous sclerosis with thickening of the lamina dura alendronate users than among the women who never
and of the alveolar crest and sclerosis of the alveolar used this drug (odds ratio 1.86, 95% CI 1.09 to 3.15).
margin.73 In contrast, the Danish study found that the use of
bisphosphonates does not increase the risk of atrial
8. Atrial fibrillation
fibrillation;80 the records of 13,586 women with a
The first indication that intravenous bisphospho- history of atrial fibrillation or flutter were surveyed
nate zoledronic acid may cause atrial fibrillation came and compared with 68,054 control women without
about during the randomized placebo-controlled trial these cardiac complications. In this study,80 3.2% of
(RCT) Health Outcomes and Reduced Incidence the women with atrial fibrillation or flutter and 2.9%
with Zoledronic Acid Once Yearly (HORIZON) of the control women were taking a bisphosphonate
Pivotal Fracture Trial.74 Patients who received the (etidronate or alendronate). The relative risk of atrial
active drug had a higher frequency of episodes of
fibrillation was 0.95 (95% CI 0.84 to 1.07).
severe atrial fibrillation compared to patients treated
with placebo, although the frequency of all cases of The fact that in two trials74,76 only the frequency
atrial fibrillation was not different between the two of severe and not of all cases of atrial fibrillation was
groups. Severe atrial fibrillation was characterized as increased by bisphosphonate therapy may indicate that
an episode of atrial fibrillation necessitating admis- bisphosphonates aggravate atrial fibrillation in patients
sion to hospital or being life-threatening or causing predisposed to it from other causes. Thus, until the
morbidity. After these findings, some of the authors probable association of bisphosphonate therapy and
of the RCT Fracture Intervention Trial75 analyzed atrial fibrillation is prospectively investigated, clini-
retrospectively the data of the study on the occur- cians should be cautious in prescribing bisphospho-
rence of atrial fibrillation during treatment with oral nates for patients with a history of atrial fibrillation
alendronate for postmenopausal osteoporosis. The or a predisposition to develop atrial fibrillation. It
analysis76 showed a trend towards increased frequency must be mentioned that on November 12, 2008, the
of severe atrial fibrillation in alendronate treated FDA announced that a review of the clinical trials
subjects compared to those treated with placebo (RR showed no clear relationship between bisphosphonate
1.51 with 95% CI 0.97 to 2.40), although the difference treatment and atrial fibrillation (serious or non-seri-
was not significant (p=0.07). The frequency of all the ous) and the FDA’s MedWatch recommended that
cases of atrial fibrillation was not different between healthcare professionals should therefore not alter
alendronate and placebo treated patients. However, their prescribing patterns for bisphosphonates and the
a later HORIZON Recurrent Fracture Trial failed patients should not stop taking their bisphosphonate
Bisphosphonate-associated adverse events 105
1999 Ocular inflammation associated with alendronate 47. Richmond BK, 2005 Profound refractory hypocalcemia
therapy. Arch Ophthalmol 117: 837-838. after thyroidectomy in a patient receiving chronic oral
33. Malik AR, Campbell SH, Toma NMG, 2002 Bilateral bisphosphonate therapy. Am Surg 71: 872-873.
acute anterior uveitis after alendronate. Br J Ophthalmol 48. Macisaac RJ, Seeman E, Herums G, 2002 Seizures after
86: 1443. alendronate. J Royal Soc Med 95: 615-616.
34. Fietta P, Manganelli P, Lodigiani L, 2003 Clodronate 49. Henley D, Kaye J, Walsh J, Cull G, 2005 Symptomatic
induced uveitis. Ann Rheum Dis 62: 378. hypocalcemia and renal impairment associated with
35. Aurich-Barrera B, Wilton L, Harris S, Shakir SW, 2006 bisphosphonate treatment in patients with multiple
Ophthalmological events in patients receiving risedronate: myeloma. Intern Med J 35: 726-728.
summary of information gained through follow-up in a 50. Berruti A, Tucci M, Generali D, et al, 2006 Management
prescription-event monitoring study in England. Drug of the side-effects of intravenous bisphosphonates: tar-
Safety 29: 151-160. geting the serum parathyroid hormone elevation. Ann
36. Adami S, Bhalla AK, Dorizzi R, 1987 The acute-phase Oncol 17: 1854-1855.
response after bisphosphonate administration. Calcif 51. http://www.fda.gov/cder/drug/infopage/bisphosphonates/
Tissue Int 41: 326-331. default.htm
37. Olson K, Van Poznak C, 2007 Significance and impact of 52. Wysowski DK, Chang JT, 2005 Alendronate and rise-
bisphosphonate-induced acute phase responses. J Oncol dronate: reports of severe bone, joint, and muscle pain.
Pharm Practice 13: 223-229. Arch Intern Med 165: 346-347.
38. Santini D, Vincenzi B, Caraglia M, Tonini G, 2007 A 53. Bock O, Boerst H, Thomasius FE, et al, 2007 Common
hitherto unreported high incidence of zoledronic acid- musculoskeletal adverse effects of oral treatment with
induced acute phase reaction in patients with cancer once weekly alendronate and risedronate in patients with
treatment-induced bone loss. Ann Oncol 18: 201-202. osteoporosis and ways for their prevention. J Musculo-
39. Miller PD, McClung MR, Macovei L, et al, 2005 Monthly skelet Neuronal Interact 7: 144-148.
oral ibandronate therapy in postmenopausal osteoporosis: 54. Gwynne Jones D, Savage R, Highton J, 2005 Synovitis
1-year results from the MOBILE study. J Bone Min Res induced by alendronic acid can present as acute carpal
20: 1315-1322. tunnel syndrome. BMJ 330: 74.
40. Schweitzer DH, Oostendorp-vande Ruit M, van der Pluijm 55. Gwynne Jones DP, Savage RL, Highton J, 2008 Alen-
G, Lowik CWGM, Papapoulos SE, 1995 Interleukin-6 dronate-induced synovitis. J Rheumatol 35: 537-538.
and the acute phase response during treatment of pa- 56. Gerster JC, 2004 Acute polyarthritis related to once-weekly
tients with Paget’s disease with the nitrogen-containing alendronate in a woman with οsteoporosis. J Rheumatol
bisphosphonate dimethylamonohydroxypoproylidine 31: 829-830.
bisphosphonate. J Bone Min Res 10: 956-962. 57. de Torrenté da la Jara G, Pécoud A, Favrat B, 2004
41. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Musculoskeletal pain in female asylum seekers and
Sewell AK, 2005 The bisphosphonate acute phase re- hypovitaminosis D3. BMJ 329: 156-157.
sponse: rapid and copious production of proinflammatory 58. Nakchbandi IA, Grey A, Masiukewicz U, Mitnick M,
cytokines by peripheral blood γδ T cells in response to Insogna K 2001 Cytokines in primary hyperparathyroid-
aminobisphosphonates is inhibited by statins. Clin Exp ism. In: Bilezikian JP, Marcus R, Levine M (eds). The
Immunol 139: 101-111. Parathyroids, Basic and Clinical Concepts. Academic
42. Srivastava T, Haney CJ, Alon US, 2009 Atorvastatin Press, San Diego, CA; pp, 411-421.
may have no effect on acute phase reaction in children 59. Edwards BJ, Gounder M, McKoy JM, 2008 Pharmaco-
following intravenous bisphosphonate infusion. J Bone vigilance and reporting oversight in US FDA fast-track
Min Res 24: 334-337. process: bisphosphonates and osteonecrosis of the jaw.
43. Harris ST, Gertz BJ, Genant HK, et al, 1993 The effect Lancet Oncol 9: 1166-1172.
of short term treatment with alendronate on vertebral 60. Marx RE, 2003 Pamidronate (Aredia) and Zoledronate
density and biochemical markers of bone remodeling in (Zometa) induced avascular necrosis of the jaws: a grow-
early postmenopausal women J Clin Endocrinol Metab ing epidemic. J Oral Maxillofac Surg 61: 1238-1239.
76: 1399-1406. 61. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL,
44. Chennuru S, Koduri J, Bauman MA, 2008 Risk factors 2004 Osteonecrosis of the jaws associated with the use of
for symtomatic hypocalcemia complicating treatment bisphosphonates: a review of 63 cases. J Oral Maxillofac
with zoledronic acid. Intern Med J 38: 635-637. Surg 62: 527-534.
45. Schussheim DH, Jacobs TP, Silverberg SJ, 1999 Hypo- 62. Bamias A, Kastritis E, Bamia C, 2005 Osteonecrosis of
calcemia associated with alendronate. Ann Intern Med the jaw in cancer after treatment with bisphosphonates:
130: 329. incidence and risk factors. J Clin Oncol 23: 8580-8587.
46. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee 63. Khosla S, Burr D, Cauley J, 2007 Bisphosphonate-as-
K, 2006 Bisphosphonate-induced hypocalcemia: report of sociated osteonecrosis of the jaw: report of a task force
3 cases and review of literature. Endocr pract 12: 48-53. of the American Society for Bone Na Mineral Research.
Bisphosphonate-associated adverse events 109
Cutaneous vasculitis induced by risedronate. Allergy 63: Bisphosphonate-associated contact stomatitis. N Engl J
1405. Med 355: e25.
96. Demerjian N, Bolla G, Spreux A, 2000 Severe oral ul- 101. Halabe A, Lifschitz BM, Azuri J, 2000 Liver damage due
cerations induced by alendronate. Clin Rheumatol 18: to alendronate 343: 365-366.
349-350. 102. Carrére C, Duvaal JL, Godard B, De Jaureguiberry
97. Gonzalez-Moles MA, Bagan-Sebastian JV, 2000 Alen- JP, Ciribilli JM, 2002 Severe acute hepatitis induced by
dronate-related oral mucosa ulcerations. J Oral Pathol alendronate. Gastroenterol Clin Biol 16: 179-180.
Med 29: 514-518. 103. Yanik B, Turkay C, Atalar H, 2007 Hepatotoxicity induced
98. Krasagakis K, Krüger-Krasagakis S, Ioannidou D, Tosca by alendronate therapy. Osteoporos Int 18: 829-831.
A, 2004 Chronic erosive and ulcerative oral lesions caused 104. Phillips MB, 2007 Risedronate-induced hepatitis. Am J
by incorrect administration of alendronate. J Am Acad Med 120: e1-2.
Dermatol 50: 651-652. 105. Wysowski DK, 2009 Reports of esophageal cancer with
99. Schmutz JL, Barbaud A, Trechot P, 2005 Alendronate et oral bisphosphonate use. N Engl J Med 360: 89-90.
ulcerations buccales: d’abord bien interroger le patient 106. Chustecka Z, 2009 Esophageal cancer in patients taking
Ann Dermatol Venereol 132: 930. oral bisphosphonates. http://www.medscape.com/view-
100. Rubegni P, Fimiani M, 2006 Images in clinical medicine. article/586127.